Title: Founder, Chief Executive Officer
Company: Nour Heart, Inc.
Location: Vienna, Virginia, United States
Dr. Salwa Elgebaly is the Founder and Chief Executive Officer at Nour Heart, Inc., and she currently holds an Adjunct Professor position at the Department of Surgery, University of Connecticut Faculty of Medicine, Farmington, Connecticut, USA, as well as a Visiting Professor position at the University of Alexandria Faculty of Pharmacy, Alexandria, Egypt. Dr. Salwa Elgebaly is a former Associate Professor and Director of Surgical Research Center at Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
Dr. Elgebaly has been recognized by Marquis Who’s Who Top Executives for dedication, achievements, and leadership in cardiovascular health.
A Research Scientist in the biomedical field, Prof. Elgebaly excels as the founder and the chief executive officer of Nour Heart, Inc., where she handles research and development for heart-related diagnostic and therapeutic products, conducts clinical trials in pharmaceutical set-up and investigative sites and submits products to the FDA for approval. Her research has resulted in the discovery of the heart-derived inflammatory mediator, Nourin as an early laboratory biomarker for the quick diagnosis of Unstable Angina (UA) and Acute Myocardial Infarction (AMI) patients experiencing chest pain, and thus, allowing crucial therapy to save muscles. Her research further identified Cyclocreatine Phosphate as a potent cardioprotective drug aimed at protecting heart patients against ischemic injury, and the anti-inflammatory agent Cyclosporin H, which protects hearts against inflammation-induced injury.
Recently, the FDA has awarded CCrP the orphan drug status with the designation for: “Prevention of Ischemic Injury to Enhance Cardiac Graft Recovery and Survival in Heart Transplantation”. CCrP is a promising first-in-class cardioprotective drug with anti-inflammatory and anti-apoptotic activities. Nour Heart, therefore, believes that CCrP will potentially have therapeutic benefits for COVID 19 patients by protecting hearts against SARS-CoV-2-triggered hypoxia/ischemia and, thus, reducing cardiac injury and infarction.
Prof. Elgebaly has written a Review article on the cardioprotective benefits of Cyclocreatine Phosphate, which was published in the Journal of Expert Review of Cardiovascular Therapy in September 2019. She is a sole inventor and contributor to nine patents issued by the U.S. Patent Office in Washington DC and three pending applications. Prof. Elgebaly has been the Principal Investigator on several research grants over $8 million in funding.
Prof. Elgebaly prepared for a career in the medical field by first earning a Bachelor of Science in pharmacy at the University of Alexandria, with honors, in 1973. After relocation to the United States, she continued with a postdoctoral fellowship and by earning a Master of Science in oncology and cancer biology at the University of Wisconsin. In 1979, Prof. Elgebaly earned a PhD in oncology and cancer biology at the University of North Carolina. In her career, she has maintained professional affiliation with a variety of organizations, including the American Heart Association, the American College of Surgeons, the American Association of Immunologists and the Society for Cardiovascular Angiography and Intervention among many other institutions.
Prof. Elgebaly attributes her success to her persistent commitment to her cause and hard work. Additionally, she has surrounded herself with a group of excellent scientists that believe in her work.
For more information, please visit:
Contact Prof. Elgebaly